Ganymed Robotics awarded a €2.5M grant from the European Commission through the EIC Accelerator Program
15.10.2021 08:00:00 EEST | Business Wire | Press release
Ganymed Robotics, a developer of advanced software and robotics technologies for orthopedic surgeons, today announces it has secured a €2,5 M grant through the European Innovation Council (EIC) Accelerator program. EIC funding will help Ganymed bring its innovation to the millions of patients suffering from arthritis.
EIC Accelerator, designed to develop and scale up ground-breaking innovations, is the most competitive public funding scheme for deeptech startups in the world, with this year over 2000 companies applying and only 65 winners.
Sophie Cahen, CEO of Ganymed Robotics, indicates: “We are thrilled by EIC Accelerator’s support which validates the high potential of Ganymed’s technology and comes as a strong recognition of the major milestones Ganymed has achieved so far. We are now in a solid position to accelerate the development of our unique, patented technology platform to bring more intelligence and efficiency into the operating room and become the new standard of care for joint replacement.”
Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics. Ganymed’s first application is a robotic surgical assistant for total knee arthroplasties (TKA). Driven by a growing and aging population, demand for orthopedic surgery is rapidly increasing and the market for TKA is expected to rise from 2.4 million procedures in 2021 to 5.7 million in 2030 in the OECD alone. Orthopedic surgeries are complex, yet 95% are performed without technological assistance, leading to sub-optimal outcomes; patient dissatisfaction rate is above 20%. Ganymed’s device is the first compact, ergonomic, and intuitive robot, simplifying, accelerating, and increasing the accuracy of orthopedics.
EIC Accelerator’s support comes at a pivotal time for Ganymed, following major successful milestones in R&D, intellectual property, product design and human resources.
The company launched a clinical trial in September 2021 to validate the company’s proprietary algorithms and collect unique in vivo data, enabling new opportunities for AI-assisted surgery. 50 patients already enrolled, with 36 more to come. Ganymed secured strategic partnerships with manufacturers to initiate the industrialization of its device. On the intellectual property front, the company obtained a patent in the United States and has 5 more pending patents, with more filings to come. Attesting of the medical community’s endorsement, two top international orthopedic surgeons personally invested in the company. Furthermore, Ganymed reinforced its management team through the recruitment of former Global R&D Director at ZimmerBiomet Michel Vernizeau, as Vice President of R&D.
The company will use the EIC funding to accelerate product development and further strengthen an already world-class team, to become global category leader in surgical orthopedics robotics by the end of the decade.
About Ganymed Robotics
Ganymed Robotics is a medical device company founded in 2018, developing the next generation of robotic assistance technologies for orthopaedic surgery. The company’s mission is to improve patient outcome, surgeon experience, and overall efficiency of care delivery for its target indications. Based in Paris, Ganymed Robotics currently employs 20 people who develop a proprietary technology platform combining computer vision, a branch of artificial intelligence, and mechatronics, in close collaboration with world-class clinicians and advisors. The first application is a robotic surgical assistant for knee arthroplasties, a common and fast-growing intervention associated with high dissatisfaction rates of above 20%. Ganymed Robotics intends to progressively deploy its technology to address several other orthopaedics indications. Ganymed Robotics won national and international innovation awards, such as I-Lab, French Tech Emergence, Deep Tech Pioneer, EIT Health, Wilco, EIC Accelerator.
For additional information: https://www.linkedin.com/company/ganymed-robotics/?originalSubdomain=fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014006089/en/
Contact information
Press
Anne Rein
Strategies & Image (S&I)
+33 6 03 35 92 05
anne.rein@strategiesimage.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Awarded $250 Million JIATF-401 Counter-UAS Contract30.9.2026 18:00:00 EEST | Press release
Echodyne, the radar platform company, today announced an indefinite-delivery/indefinite-quantity (IDIQ) contract supporting the Joint Interagency Task Force 401’s (JIATF-401) Domestic Shield program. The agreement has a $250 million ceiling and an ordering period of up to 36 months, providing a path to acquire counter-unmanned aircraft system (C-UAS) capabilities for force protection, base defense and counter-drone operations in the United States and abroad. As part of the agreement, Echodyne’s advanced MESA radars will be available for procurement on JIATF-401’s C-UAS Marketplace for U.S. and Allied Nations. At the center of Echodyne’s radar portfolio is MESA, its software-defined metamaterials electronically scanned array architecture. MESA combines precise electronic beam steering with a compact, solid-state design, delivering high-fidelity radar data without the size, weight, power and cost traditionally associated with high-performance ESA radar. Its architecture supports continuo
AM Green Named Winner of Asian Lot in H2Global Auction Funded by German Government30.9.2026 17:46:00 EEST | Press release
AM Green Ammonia (India) Private Limited ("AM Green") has been selected as the sole winner of the Asian lot in the H2Global auction run by HINT.CO GmbH ("Hintco"), securing a long-term purchase agreement for the supply of Renewable Fuels of Non-Biological Origin (RFNBO) ammonia to Germany. The award follows a competitive bidding process in which AM Green’s offer was ranked first among the submissions received. Over a period of 10 years, Hintco will purchase ammonia from AM Green for a minimum value of EUR 585 million. Hintco may purchase additional quoted volumes from AM Green using proceeds generated from the resale of green ammonia in the European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930707955/en/ Left to right: Timo Bollerhey, CEO of Hintco and Co-Founder of H2Global, and Gautam Reddy, CEO of AM Green Ammonia, mark AM Green’s selection as the sole winner of the Asian lot in the H2Global auction for th
Tangent Robotics Raises 4.5M in Pre-seed Funding to Advance Fine Motor Skills for Robot Dexterity30.9.2026 17:23:00 EEST | Press release
In humans, fine motor skills can take two decades to fully develop. Tangent Robotics, which today announced its pre-seed funding round, aims to speed up the timeline for robots. The company will use the funds to develop skilled robotic manipulation capabilities at the intersection of hand hardware, touch sensing, and motor learning, and deploy them in demanding manufacturing environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930237631/en/ Tangent Robotics is developing fine motor skills for robot hands, which unlock the ability to perform critical tasks for what we want our economy to build locally, fast and at scale "Fine motor skills are hard to learn, and represent a layer that is currently missing in robotics but omnipresent in the real world," says Pedro Piacenza, Tangent's co-founder. "They unlock the ability to perform delicate, intricate manipulation. Tasks like assembly, threading, connector mating, gas
Blue Matter Launches Behavioral Science Center of Excellence to Decode and Predict Health Care Decisions in a Rapidly Evolving Biopharma Landscape30.9.2026 16:00:00 EEST | Press release
Blue Matter today announced the launch of its Behavioral Science Center of Excellence (BeSci CoE), a specialized capability within the Blue Matter Insights primary market research team. The CoE applies behavioral science as a strategic lens to decode the “why” behind the decisions made by healthcare professionals, patients, care partners, and other stakeholders. Biopharma decisions hinge on knowing why customers do what they do. Traditional research does a good job of capturing what stakeholders say but often misses the unconscious drivers, biases, emotions, and contexts that shape behavior. The result is an incomplete picture in the moments where clarity matters most, including when developing positioning strategies, planning product launches, and making major lifecycle decisions. "You don't need a survey to tell you that physicians see efficacy as the most important treatment decision driver," said Andrew Pilecki, Ph.D., Senior Market Research Director at Blue Matter. "What our clien
934 Embeds Bluefin Payment Security into Juno to Advance Secure, Connected Hospitality Payments30.9.2026 16:00:00 EEST | Press release
Bluefin, a global leader in payment and data security, and 934, a global provider of connected payment technology for the hospitality industry, today announced a partnership to integrate Bluefin’s payment security capabilities into Juno, 934’s hospitality payment platform. Hospitality businesses increasingly operate across connected payment environments spanning hotels, restaurants, resorts and other guest experiences. Behind those interactions are multiple systems, workflows and payment technologies that must work together while protecting sensitive payment data. Juno is designed to connect those experiences through a unified hospitality payment environment. By incorporating Bluefin’s security technology into the platform architecture, 934 can provide customers globally with access to PCI-validated point-to-point encryption (P2PE) for card-present payments and tokenization for protecting sensitive payment data. The result is a security-first approach in which payment protection is bui
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom